2Seventy Bio Inc
NASDAQ:TSVT

Watchlist Manager
2Seventy Bio Inc Logo
2Seventy Bio Inc
NASDAQ:TSVT
Watchlist
Price: 3.05 USD -0.33% Market Closed
Market Cap: 157.3m USD
Have any thoughts about
2Seventy Bio Inc?
Write Note

2Seventy Bio Inc
Other Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

2Seventy Bio Inc
Other Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
2Seventy Bio Inc
NASDAQ:TSVT
Other Operating Expenses
-$235k
CAGR 3-Years
N/A
CAGR 5-Years
40%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Operating Expenses
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Other Operating Expenses
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Other Operating Expenses
-$189m
CAGR 3-Years
-4%
CAGR 5-Years
-99%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Operating Expenses
$49.6m
CAGR 3-Years
336%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Operating Expenses
-$37.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

2Seventy Bio Inc
Glance View

Market Cap
157.1m USD
Industry
Biotechnology

2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 437 full-time employees. The company went IPO on 2021-10-18. The firm is focused on the research, development, and commercialization of transformative treatments for cancer. Its approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. The company is advancing multiple preclinical and clinical programs in oncology. The firm's lead preclinical programs in B cell non-Hodgkin's lymphoma (B-NHL) and acute myeloid leukemia are illustrations of its multiplex approach applied to address the specific challenges of treating those cancers. The company is developing bbT369 product candidate as a treatment for patients with B-NHL.

TSVT Intrinsic Value
5.63 USD
Undervaluation 46%
Intrinsic Value
Price

See Also

What is 2Seventy Bio Inc's Other Operating Expenses?
Other Operating Expenses
-235k USD

Based on the financial report for Dec 31, 2023, 2Seventy Bio Inc's Other Operating Expenses amounts to -235k USD.

What is 2Seventy Bio Inc's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
40%

Over the last year, the Other Operating Expenses growth was -18%.

Back to Top